Last reviewed · How we verify
Ankaferd Blood Stopper as a New Strategy to Avoid Early Complication After Transradial Coronary Angiography: A Randomized, Placebo-Controlled Clinical Trial
In 2008 Goker et al, introduced Ankaferd Blood Stopper (ABS) as a new hemostatic drug. Recently, ABS has been shown to produce local hemostasis by implementing topically after major arterial vessel injury. Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO. To test this hypothesis the investigators planned a three arm randomized study to evaluate the safety and efficacy of Ankaferd blood stopper in adjunct to short-time compression, compared to either short-time compression with conventional sterile gauzes or with a TR band after transradial diagnostic procedures.
Details
| Lead sponsor | Acibadem University |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 600 |
| Start date | 2016-11 |
| Completion | 2017-12 |
Conditions
- Radial Artery Injury
- Hematoma
- Bleed
Interventions
- ABS
- TR Band
- CS
Primary outcomes
- Radial artery occlusion assessed by reverse Barbeau's test — 24 hours
Countries
Turkey (Türkiye)